Introduction
============

Non-autoimmune sacroiliac joint (SIJ) dysfunction is increasingly recognized as an important cause of chronic low back pain, with prevalence estimates of 15--30%[@b1-mder-11-113]--[@b5-mder-11-113] and a known female predominance.[@b6-mder-11-113],[@b7-mder-11-113] SIJ pain reduces quality of life to an extent similar to other spine conditions.[@b8-mder-11-113],[@b9-mder-11-113] Nonsurgical treatments include physical therapy, chiropractic, intra-articular SIJ steroid injections, prolotherapy, and radiofrequency neurotomy of sacral nerve root branches. These treatments have some literature support,[@b10-mder-11-113]--[@b15-mder-11-113] but high-quality evidence supporting long-term improvements is lacking.

Minimally invasive sacroiliac joint fusion (SIJF) is an increasingly accepted surgical option for SIJ dysfunction. To date, improvement in pain, disability, and quality of life has been demonstrated in three prospective clinical trials[@b16-mder-11-113]--[@b18-mder-11-113] as well as numerous case series[@b19-mder-11-113]--[@b24-mder-11-113] and comparative case series.[@b25-mder-11-113]--[@b27-mder-11-113]

Although multiple devices are now available for SIJF, the majority of reported literature describes the use of porous triangular titanium implants (TTI). Long-term studies reporting SIJF with TTI include a 3-year multicenter retrospective cohort,[@b28-mder-11-113] a 5-year single-center case series,[@b29-mder-11-113] and a 6-year comparative case series.[@b30-mder-11-113] The 6-year cohort included long-term follow-up in patients who were unable to undergo SIJF due to insurance coverage denials; this cohort showed worsened pain and disability scores, with worse working status and increased opioid use.

Long-term follow-up of patients enrolled in prospective clinical trials is a valuable but often challenging task. Herein, we report a prospective 3-year follow-up of subjects undergoing SIJF as part of two US prospective multicenter trials (Investigation of Sacroiliac Fusion Treatment \[INSITE\] and Sacroiliac Joint Fusion with iFuse Implant System \[SIFI\]). Follow-up is ongoing, and radiographic follow-up (with 5-year computed tomography \[CT\] scans) will be reported later.

Methods
=======

Participants
------------

Subjects included in this study (Long Term Outcomes from INSITE and SIFI \[LOIS\], NCT02270203) were enrolled at 12 centers who participated in either INSITE or SIFI. To participate, a site had to have enrolled and treated at least five patients with SIJF; have sufficient clinical trial resources, including a dedicated study investigator and coordinator who could carry out trial requirements; and the ability to maintain meaningful enrollment and follow-up for this long-term study. Of 39 sites participating in INSITE and SIFI, 12 sites met criteria of study participation. Participants were screened for study eligibility criteria and those not meeting all criteria (screen failures) or who refused participation were tabulated.

INSITE is a prospective multicenter randomized trial of SIJF vs. non-surgical management whose 2-year results showed high degrees of improvement in pain, disability, and quality of life in the surgical group but only modest responses in the non-surgical group.[@b16-mder-11-113] SIFI is a prospective multicenter single-arm clinical trial evaluating the same procedure/device; the follow-up schedule and assessments were nearly identical, and 2-year results were similarly positive.[@b18-mder-11-113] A pooled analysis of these trials (along with a randomized trial from Europe[@b17-mder-11-113]) showed marked homogeneity of study results.[@b31-mder-11-113]

INSITE/SIFI subjects at participating centers were approached regarding participation in LOIS. To qualify, a subject had to have undergone SIJF with TTI within the INSITE or SIFI studies and sign a LOIS-specific informed consent form. As reported previously, enrollment in INSITE and SIFI required a diagnosis of SIJ dysfunction due to degenerative sacroiliitis or SIJ disruption that included elements of history, a positive Fortin finger test,[@b32-mder-11-113] at least three positive physical examination signs suggestive of SIJ dysfunction, and a positive diagnostic SIJ block performed under fluoroscopic or CT guidance. Key exclusion criteria were severe low back or hip pain due to other conditions, SIJ dysfunction due to autoimmune or inflammatory conditions and osteoporosis.[@b16-mder-11-113],[@b18-mder-11-113]

Interventions and assessments
-----------------------------

Study follow-up in LOIS consists of phone calls postoperatively at years 2.5, 3.5, and 4.5 as well as in-clinic study visits at years 3, 4, and 5. Phone calls were intended to maintain subject contact and assess for adverse events. At in-clinic visits, subjects completed surveys to assess SIJ pain and low back pain scores (identical visual analog scale \[VAS; 0--100 scale\]), Oswestry Disability Index (ODI), quality of life (EuroQol-5D \[EQ-5D\] time trade-off \[TTO\] index, a health state utility value ranging from \<0 \[death\] to 1 \[perfect health\]), and satisfaction. All questionnaires were administered by trained study research coordinators.

Subjects were also queried regarding the occurrence of adverse events, defined using an international standard (ISO14155:2011). Both sites and study monitors also reviewed medical records to ensure complete adverse event reporting during follow-up study. For each event, the site investigator was required to assess severity and relatedness to their SIJF or preexisting condition. Relatedness to a device or procedure was characterized as definitely, probably, possibly, unlikely, or not related.

Herein, we report 3-year clinical, functional, and safety outcomes. The 5-year visit, which includes a high-resolution CT scan of the pelvis, will be reported elsewhere.

All centers obtained approval from applicable institutional review boards (IRB) ([Table S1](#SD1-mder-11-113){ref-type="supplementary-material"}) for the extension study prior to participation. Subjects were recompensed nominal amounts for time and expense to complete study visit and call requirements, as approved by each site's governing IRB. The study was sponsored by the device manufacturer (SI-BONE, Inc., San Jose, CA, USA). All study sites underwent remote and regularly scheduled on-site data monitoring visits by sponsor representatives; all collected data were verified against source documents at the site.

The primary efficacy success end point for this study is a composite success end point at 3, 4, and 5 years defined as a reduction from preoperative VAS SIJ pain score of at least 20 points, absence of device-related serious adverse events, absence of neurological worsening, and absence of surgical revision. Note that the primary end point used was identical to that used in the component trials (INSITE and SIFI), where the primary clinical end points were evaluated at 6 months. Other outcomes included improvements in VAS SIJ pain score, ODI,**[@b33-mder-11-113]** EQ-5D score,[@b34-mder-11-113] proportion of non-working subjects who return to work, and occurrence of serious adverse events.

Statistical analysis
--------------------

A standard approach to statistical analysis was used to calculate standard aspects of change scores and binary outcomes. Repeated measures analysis of variance, which simultaneously takes into account multiple measurements per subject, was used to determine statistical significance of changes from baseline, where relevant binary outcomes were measured with a chi-squared test, McNemar's test, or exact binomial confidence intervals.

Results
=======

Of 127 potentially eligible INSITE/SIFI subjects, 103 were enrolled in LOIS. Reasons for non-participation included inability to participate due to health issues (n=2), death prior to screening (n=3), lost to follow-up on previous study (n=4), moved out of state (n=1), refused study participation (n=11), planning pregnancy (n=1), previous withdrawal from INSITE or SIFI (n=1), and unlikely to be compliant (n=1). Of the 103 participating subjects, 96 (93%) subjects had 3-year follow-up visits. Reasons for lack of follow-up included loss to follow-up (n=5), death due to other causes (n=2), and withdrawal of consent (n=1).

All enrolled subjects met study eligibility criteria. There were no meaningful differences in baseline demographic characteristics for subjects enrolled in LOIS vs. those enrolled in the original trials ([Table 1](#t1-mder-11-113){ref-type="table"}). Two-year responses to SIJF were slightly larger in subjects participating at LOIS sites compared to those who did not participate (improvement in VAS SIJ pain of 62.3 vs. 48.0 points, *p*\<0.0001; improvement in ODI of 28.8 vs. 23.9 points, *p*=0.0776). There were no meaningful differences in the cohort enrolled versus subjects completing the 3-year visit (not shown). Subjects (mean age 51 years) were mostly Caucasians (97%) and female (73%). Subjects had high preoperative pain scores (mean \[SD\] of 81.5 \[12.6\]) and high levels of disability (ODI score 56.3 \[12.1\]). The duration of pain prior to enrollment averaged 5.7 years. EQ-5D at baseline was 0.45 (0.17), indicating a very poor quality of life.[@b8-mder-11-113] In all, 77% of subjects were taking opioids for back or SIJ pain preoperatively and 45% had a history of lumbar fusion, and concomitant spine and hip disease was common. Most (93, 90.3%) patients underwent unilateral SIJF on either of the treatment studies; 10 (9.7%) patients had qualifying pain, physical examination signs, and diagnostic blocks consistent with bilateral SIJ dysfunction and therefore underwent bilateral SIJF. Pain but not ODI scores between months 6 and 24 was slightly lower at sites that participated in the current study vs. those that did not (not shown).

At 3 years, the mean SIJ pain score had decreased to 26.2, representing a mean change from preoperative score of 55 points (*p*\<0.0001; [Figure 1](#f1-mder-11-113){ref-type="fig"}). In all, 71 (86%) subjects met the primary efficacy success composite end point. The mean ODI score decreased from 56 preoperatively to 28 at 3 years, an improvement of 28 points (*p*\<0.0001). In all, 60 (72.3%) subjects had improvement in ODI scores of at least 15 points from their preoperative score. Compared to subjects who did not participate in this long-term follow-up study, participants in the current study had slightly larger 24-month improvements in SIJ pain and ODI (62.3 vs. 48.0 points, *p*\<0.0001; improvement in ODI of 28.8 vs. 23.9 points, *p*=0.0776). Had all subjects in INSITE/SIFI participated, estimated responses over all follow-up would have been slightly smaller (by 8 or fewer points for VAS SIJ pain \[0--100 scale\] and 3.2 or fewer points for ODI). EQ-5D TTO index improved by 0.30 points (*p*\<0.0001).

Satisfaction rates with the iFuse result were high (96% subjects were very or somewhat satisfied at 3 years; [Figure 2](#f2-mder-11-113){ref-type="fig"}). The proportion of patients who would definitely undergo the procedure again was high at 24 months (87%) and lower at month 36 (73%, *p*=0.003 for change from month 24 to month 36). Satisfaction rates correlated with improvement in SIJ pain and ODI. Work status (i.e., the proportion of subjects working full- or part-time outside the home) at 36-month follow-up was unchanged compared to baseline (McNemar *p*=0.1814; [Figure 3](#f3-mder-11-113){ref-type="fig"}).

To date, 168 adverse events were reported in 75 subjects, most of which were unrelated to the pelvis or spine. Of the 22 events involving the pelvis, one involved bilateral SIJ pain, five reported ipsilateral SIJ pain, one was potentially related to the index SIJ and 15 reported SIJ pain contralateral to the index side. One subject, who experienced only modest temporary SIJ pain relief, underwent revision of the index side at year 3.7 at the subject's request by a non-study physician. Imaging showed excellent device placement and no radiolucency; the investigator believed that progressive lumbar scoliosis contributed to the subject's pain. Five subjects underwent treatment of contralateral SIJ pain with SIJF. No subject had an event rated as related to the iFuse implant or placement procedure. One subject had worsening lumbar facet pain rated as probably related to a non-surgical SIJ procedure. There were no severe device- or procedure-related adverse events.

Discussion
==========

SIJ dysfunction markedly impacts quality of life[@b8-mder-11-113] and is potentially treatable with both non-surgical and surgical approaches. However, the condition is often overlooked as an etiology of axial back pain, primarily because, until recently, no surgical treatment had been shown to provide adequate long-term pain relief with an acceptable recovery profile. With the advent of minimally invasive SIJF, familiarity and interest in the condition have grown and specialty society guidelines are now available.[@b35-mder-11-113],[@b36-mder-11-113] Published literature confirming the safety and effectiveness of SIJF is expanding and now includes two prospective multicenter randomized trials,[@b16-mder-11-113],[@b17-mder-11-113] a prospective multicenter single-arm trial[@b18-mder-11-113] and multiple case series.[@b19-mder-11-113]--[@b30-mder-11-113]

Herein, we report 3-year follow-up of subjects who participated in two 24-month prospective multicenter US trials (one randomized trial[@b16-mder-11-113] and one prospective single-arm trial[@b18-mder-11-113]). We observed ongoing improvements in SIJ pain, disability, and quality of life, which appear to be durable over time. These improvements were relatively large and similar to those observed in other commonly performed spine surgery procedures. Satisfaction rates were high, and very few patients had SIJ-related complaints that required surgical treatment. The proportion of subjects who stated they would definitely have the procedure again was significantly less at month 36 compared to month 24; the reason for this is not known. SIJF did not affect work status overall.

In all, 15% of subjects reported SIJ pain contralateral to the index side during the study. Our study cannot determine which of the following could pertain: 1) the same degenerative process that affected the index side affected the contra-lateral side; 2) the subject had bilateral pain at baseline with only one (the index) side qualifying for surgery within the study; 3) increased activity as a result of successful index side surgery may exacerbate the contralateral SIJ; or 4) fusion of the index side biomechanically accelerates degeneration of the contralateral side, a variant on adjacent segment degeneration. A biomechanical study showed that SIJF does not significantly alter the loading across the contralateral SIJ, suggesting no increase in the likelihood of adjacent segment degeneration.[@b37-mder-11-113] Our data provide little evidence that SIJF increases the risk of hip or lumbar spine pathology. One subject underwent revision surgery of the index side at his request by a non-study physician.

Our results are similar to those observed in several other retrospective case series,[@b28-mder-11-113]--[@b30-mder-11-113] which have reported positive long-term (\>24-month) outcomes. In a multicenter cohort, sustained positive outcomes and relatively low ODI scores were reported.[@b28-mder-11-113] A small cohort of patients at 5 years showed low pain scores and high rates of bony fusion.[@b29-mder-11-113] In a comparative cohort study conducted in Spain, patients who underwent SIJF demonstrated improvements in pain, disability, work status, and opioid use in comparison with patients undergoing continued conservative management who experienced worsened pain, disability, and work status as well as increased opioid use.[@b30-mder-11-113]

Although the diagnosis of SIJ-mediated back/buttocks pain is often described as being challenging, our results suggest that SIJ dysfunction can not only be reliably diagnosed (through a combination of history, physical examination, and response to diagnostic SIJ block\[s\]) but also effectively treated.

The major advantage of this study is the prospective long-term follow-up of a relatively large number of subjects from a variety of treatment settings undergoing SIJF in two prospective clinical trials. The primary disadvantage is the lack of long-term data from a concurrent control group receiving only non-surgical treatment. In the INSITE study, most subjects in the non-surgical control group who experienced inadequate pain relief at month 6 crossed over to surgical care. However, long-term non-surgical follow-up appears to be associated with very poor outcomes.[@b30-mder-11-113] Another limitation is that several sites in INSITE and SIFI could not participate in the current study due to either low numbers of subjects or lack of clinical trial resources; subjects at participating sites had slightly larger 24-month improvements in SIJ pain and ODI compared to those at non-participating sites. The calculated impact on 3-year scores reported herein was small -- approximately 4 points for VAS SIJ pain and 2.4 points for ODI. Another limitation is that the data from this study of triangular implants are not applicable to clinical outcomes from devices with other designs and fusion strategies for SIJF.

Conclusion
==========

In this prospective study, improvements in pain, disability, and quality of life were sustained at 3 years after SIJF with TTI. Satisfaction rates were high.
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Institutional review boards that approved this study

  Site ID   Site name                                 Approving Institutional Review Board (IRB)
  --------- ----------------------------------------- --------------------------------------------
  **1**     Columbia Orthopedics                      Washington University St. Lois
  **5**     Medical University of South Carolina      Medical University of South Carolina
  **7**     Gordon Spine                              Western IRB
  **16**    Resurgens Orthopaedics                    Western IRB
  **27**    Orthopedics of Oklahoma                   Western IRB
  **35**    Orthopaedic Center of Southern Illinois   Western IRB
  **36**    Integrated Spine Care                     Wheaton Franciscan IRB
  **38**    Yale University                           Yale University IRB
  **47**    Aurora BayCare Orthopedics                Western IRB
  **48**    Bluegrass Orthopedics                     Western IRB
  **58**    Allegheny Medical Center                  Western IRB
  **60**    Overtake Hospital                         Western IRB
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![Mean VAS SIJ pain (top), ODI (middle), and EQ-5D (bottom) by time.\
**Note:** Data from baseline through month 24 are from subjects' participation in INSITE[@b16-mder-11-113]/SIFI[@b18-mder-11-113].\
**Abbreviations:** EQ-5D TTO Index, EuroQol-5D time trade-off index; INSITE, Investigation of Sacroiliac Fusion Treatment; ODI, Oswestry Disability Index; SIJ, sacroiliac joint; SIFI, Sacroiliac Joint Fusion with iFuse Implant System; VAS, Visual Analogue Scale.](mder-11-113Fig1){#f1-mder-11-113}

![Three-year ratings of satisfaction with outcomes of SIJF (left) and whether subjects would have procedure again (right).\
**Abbreviation:** SIJF, sacroiliac joint fusion.](mder-11-113Fig2){#f2-mder-11-113}

![Work status by months after SIJF.\
**Abbreviation:** SIJF, sacroiliac joint fusion.](mder-11-113Fig3){#f3-mder-11-113}

###### 

Baseline and surgical characteristics of LOIS participants compared to original trials

  Characteristic                               LOIS (n=103)   INSITE/SIFI (n=274[a](#tfn1-mder-11-113){ref-type="table-fn"})   *p*-value[b](#tfn2-mder-11-113){ref-type="table-fn"}
  -------------------------------------------- -------------- ---------------------------------------------------------------- ------------------------------------------------------
  Baseline characteristics                                                                                                     
   Age, years, mean (SD)                       50.8 (10.8)    50.6 (11.3)                                                      0.7921
   Female, n (%)                               75 (72.8)      195 (71.2)                                                       0.6812
   Body mass index, mean (SD)                  31.0 (7.4)     29.7 (6.5)                                                       0.0225
   Non-white race, n (%)                       3 (2.9)        11 (4.0)                                                         0.5439
   Hispanic, n (%)                             3 (3.9)        11 (4.0)                                                         0.5439
   History of prior lumbar fusion, n (%)       46 (44.7)      117 (42.7)                                                       0.6166
   Current smoker, n (%)                       19 (18.4)      70 (25.5)                                                        0.1128
   Pain began in peripartum period, n (%)      14 (13.6)      28 (10.2)                                                        0.3657
   Pain duration, years, mean (SD)             5.7 (6.8)      5.8 (6.9)                                                        0.8345
   VAS SIJ pain, mean (SD)                     81.5 (12.6)    80.8 (12.5)                                                      0.4536
   ODI, mean (SD)                              56.3 (12.1)    55.9 (12.0)                                                      0.7241
   EQ-5D TTO index, mean (SD)                  0.45 (0.17)    0.43 (0.18)                                                      0.2405
  Surgical characteristics                                                                                                     
   Right side, n (%)                           42 (40.8)      97 (56.7)                                                        0.0126
   Bilateral SIJF, n (%)                       10 (9.7)       38 (13.9)                                                        0.1495
   Operative duration (minutes), mean (SD)     46.3 (16.4)    45.7 (20.0)                                                      0.8011
   Hospital length of stay (days), mean (SD)   0.72 (0.93)    0.83 (0.98)                                                      0.3124
   Number of implants, n (%)                                                                                                   
    2                                          2 (1.9)        9 (5.3)                                                          \<0.0001
    3                                          80 (77.7)      157 (91.8)                                                       
    4                                          21 (20.4)      5 (2.9)                                                          

**Notes:**

172 subjects in SIFI+102 subjects in INSITE assigned to SIJF.

Comparing participants vs. non-participants.

**Abbreviations:** EQ-5D TTO index, EuroQol-5D time trade-off index; INSITE, Investigation of Sacroiliac Fusion Treatment; LOIS, Long Term Outcomes from INSITE and SIFI; ODI, Oswestry Disability Index; SIFI, Sacroiliac Joint Fusion with iFuse Implant System; SIJF, sacroiliac joint fusion; SIJ, Sacroiliac Joint Pain; VAS, Visual Analogue Scale.
